SEC Form 4 · accession 0001193125-26-357383
Artiva Biotherapeutics, Inc. · ARTV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Subhashis Banerjee
Officer — Chief Medical Officer
Period of report
Aug 18, 2026
Accepted (ET)
Aug 19, 2026 · 9:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001817241
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 18, 2026 | M | 429 | $1.92 | A | 145,392 | D | |
| Common Stock | Aug 18, 2026 | S | 429 | $12.00 | D | 144,963 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $1.92 | Aug 18, 2026 | M | 429 | D | — | Apr 7, 2035 | Common Stock | 429 | 79,571 | D |
Explanation of responses
- F1The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026.
- F225% of the shares initially subject to the option vested and became exercisable on April 8, 2026, and the balance of the shares subject to the option are vesting and becoming exercisable at a rate of 1/36th per month over the following 36 months.